Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Biodynamics: Peter Pack

Oxford BioDynamics has appointed Peter Pack as independent non-executive chairman of the firm. He will be replacing Stephen Diggle, who will transition to the role of non-executive director. Prior to joining the firm's board in 2019 as non-executive director, Pack headed Crescendo Biologics from 2015 to 2019. Pack also served as cofounder and CEO of MTM laboratories prior to its acquisition by Roche Diagnostics. Before launching MTM laboratories, Pack began his career at MorphoSys. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.